A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.

Phase 1/2 Recruiting 130 enrolled Beijing Mabworks Biotech Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase I/II study designed to evaluate the safety, tolerability, PK and PD of subcutaneous MIL116, an anti-APRIL monoclonal antibody, in healthy participants and patients with IgA Nephropathy.

Timeline

Start: 2026-02-05
Primary completion: 2028-06
Completion: 2029-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MIL116	Monoclonal antibody	—	Subcutaneous

A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.

Summary

Timeline

Drugs

Indications